Antibiotics: A new spanner in the works of bacterial transcription
Bacterial infections cause over 17 million deaths globally every year (Butler and Buss, 2006; World Health Organisation, 2014). In the past 70 years, antibiotics have been critical in the fight against infectious disease, yet alarmingly, pathogenic bacteria of all categories have developed antibiotic resistance. This is rated one of the greatest threats to human health.
Alongside the rise of antibiotic resistant variants of already existing diseases, such as MDR-TB (multi-drug resistant tuberculosis) and MRSA (methicillin-resistant Staphylococcus aureus), new infectious diseases are emerging every year. However, few new antibiotics have been developed over the past two decades (Chief Medical Officer’s report, 2011). The situation is further complicated by the fact that many current antibiotics have severe side effects, particularly if they are used for a long time. There is, therefore, an urgent need for novel drugs. Now, in eLife, Richard Ebright and colleagues from Rutgers University, the Helmholtz Centre for Infection Research, and Naicons Srl—including Yu Zhang, David Degen, and Mary Ho as joint first authors—use a combination of genetic, biochemical and structural approaches to characterise how a recently discovered compound, with very promising properties, works (Zhang et al., 2014).
Designing drugs in a rational, systematic way requires an intimate knowledge of how they interact with their target and the mechanism by which they inhibit this target’s activity. Antibiotics act by interfering with processes that are essential to cells, such as transcription (Darst, 2004), translation or cell wall synthesis. In effect, these drugs ‘throw a spanner in the works’ of the bacterial cell. One set of prime targets for antibiotics are enzymes called multisubunit RNA polymerases (RNAPs), which transcribe the cellular genomes of all life on Earth (Werner and Grohmann, 2011).
The natural genetic mutations that constantly occur in all organisms mean that although a new antibiotic may initially successfully kill bacteria, it may not remain effective for long. Mutations that stop antibiotics inhibiting bacterial RNAP emerge randomly regardless of the environment the bacteria grow in. In most cases these changes will also make the bacterium less fit. Therefore, if the bacteria are not exposed to antibiotics, the number of resistant bacteria remains low compared to the number that are sensitive to the antibiotic (Comas et al., 2012). However, if antibiotics are then targeted at these bacteria, the selective pressure of the drug treatment may increase the proportion of drug-resistant mutants in the overall population, and thus a drug resistant strain of bacteria will emerge over time. In addition, the initial loss of fitness associated with the drug-resistant mutations is often compensated for by additional mutations, and so a new and more dangerous pathogen can evolve (Comas et al., 2012).
The ideal molecular target of an antibiotic—its binding site—would present little opportunity for drug resistance to evolve. Therefore, the target should be small, and directly involved in how RNAP works as an enzyme, to reduce the likelihood of a drug resistant RNAP evolving that remains catalytically active.
The bacterium Actinomadura sp., which was originally isolated from a soil sample, produces an antimicrobial chemical called GE23077, henceforth referred to as GE (Ciciliato et al., 2004). GE is Actinomadura’s weapon in the fight for resources in its natural environment, and is used against fungi as well as Gram-negative and Gram-positive bacteria. Early studies demonstrated that GE was a potent inhibitor of RNAP purified from Escherichia coli. However, the compound was less effective against living cells as it is unable to cross the cellular envelope that surrounds a bacterium (Sarubbi et al., 2004). Improving GE’s properties, for example by increasing its uptake into a cell while not lowering its potency, requires the molecular basis of its activity to be thoroughly understood (Mariani et al., 2005).
RNAPs transcribe DNA by building long chains of RNA from individual nucleotides. GE, like another antibiotic called rifampin (Rif) that is used to treat tuberculosis, does not interfere with the first steps of transcription initiation. Therefore, RNAP can still find the correct start site and load the template DNA strand into its active site ready for RNA synthesis. GE inhibits the subsequent step, preventing the joining together of the first two nucleotide substrates in the RNA chain.
The X-ray crystal structures of bacterial RNAP in complex with GE solved by Ebright and colleagues provide a structural explanation for this activity (Figure 1). GE binding to RNAP interferes with the binding of the first and second RNA nucleotide substrates to the enzyme. Rif works in a similar way: as this antibiotic’s binding site is close to, but offset from GE’s, Rif allows the formation of di-and tri-nucleotides but prevents the synthesis of longer RNA chains. GE also interferes with the binding of a magnesium ion in the RNAP active site that is critical for enzyme catalysis.
To assess the number of mutations at the binding site that confer GE resistance and thereby pose a threat to effective antibiotic treatment, Ebright and colleagues used a technique called saturation mutagenesis. This generates all the possible mutations at a specific site, in this case within 30 Å of the catalytic centre of E. coli RNAP. The analysis revealed a very small target-based resistance spectrum, as only a very few mutations could produce RNAPs that are both resistant to GE and still catalytically active. The GE target site is also roughly 10-fold smaller than that of Rif and is therefore superior as it presents fewer possible sites of mutation.
Since the GE and Rif binding sites are next to but distinct from each other, the two drugs do not display cross-resistance. Therefore, Rif resistant RNAPs are not resistant to GE, and vice versa. Moreover, GE and Rif can bind simultaneously to RNAPs. As the ‘icing on the cake’ of their work, Ebright and colleagues joined together GE and Rif to generate a novel two-part (bipartite) compound, Rifa-GE. While Rifa-GE is as potent as GE or Rif, it also effectively inhibits RNAP variants that are resistant to either.
Once GE-containing compounds have been modified so they are better able to enter a living bacterial cell, they are likely to become front-line drugs in the struggle against bacterial infections.
References
-
Natural products—the future scaffolds for novel antibiotics?Biochemical Pharmacology 7:919–929.https://doi.org/10.1016/j.bcp.2005.10.012
-
New inhibitors targeting bacterial RNA polymeraseTrends in Biochemical Sciences 29:159–160.https://doi.org/10.1016/j.tibs.2004.02.005
-
Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: chemical derivatizationBioorganic & Medicinal Chemistry Letters 15:3748–3752.https://doi.org/10.1016/j.bmcl.2005.05.060
-
Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymeraseEuropean Journal of Biochemistry/FEBS 271:3146–3154.https://doi.org/10.1111/j.1432-1033.2004.04244.x
-
Evolution of multisubunit RNA polymerases in the three domains of lifeNature Reviews Microbiology 9:85–98.https://doi.org/10.1038/nrmicro2507
Article and author information
Author details
Publication history
- Version of Record published: April 22, 2014 (version 1)
Copyright
© 2014, Arnvig and Werner
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,478
- Page views
-
- 63
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Apoptosis signal-regulating kinase 1 (ASK1) is a crucial stress sensor, directing cells toward apoptosis, differentiation, and senescence via the p38 and JNK signaling pathways. ASK1 dysregulation has been associated with cancer and inflammatory, cardiovascular, and neurodegenerative diseases, among others. However, our limited knowledge of the underlying structural mechanism of ASK1 regulation hampers our ability to target this member of the MAP3K protein family towards developing therapeutic interventions for these disorders. Nevertheless, as a multidomain Ser/Thr protein kinase, ASK1 is regulated by a complex mechanism involving dimerization and interactions with several other proteins, including thioredoxin 1 (TRX1). Thus, the present study aims at structurally characterizing ASK1 and its complex with TRX1 using several biophysical techniques. As shown by cryo-EM analysis, in a state close to its active form, ASK1 is a compact and asymmetric dimer, which enables extensive interdomain and interchain interactions. These interactions stabilize the active conformation of the ASK1 kinase domain. In turn, TRX1 functions as a negative allosteric effector of ASK1, modifying the structure of the TRX1-binding domain and changing its interaction with the tetratricopeptide repeats domain. Consequently, TRX1 reduces access to the activation segment of the kinase domain. Overall, our findings not only clarify the role of ASK1 dimerization and inter-domain contacts but also provide key mechanistic insights into its regulation, thereby highlighting the potential of ASK1 protein-protein interactions as targets for anti-inflammatory therapy.
-
- Biochemistry and Chemical Biology
Activation of the extracellular signal-regulated kinase-2 (ERK2) by phosphorylation has been shown to involve changes in protein dynamics, as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) and NMR relaxation dispersion measurements. These can be described by a global exchange between two conformational states of the active kinase, named ‘L’ and ‘R,’ where R is associated with a catalytically productive ATP-binding mode. An ATP-competitive ERK1/2 inhibitor, Vertex-11e, has properties of conformation selection for the R-state, revealing movements of the activation loop that are allosterically coupled to the kinase active site. However, the features of inhibitors important for R-state selection are unknown. Here, we survey a panel of ATP-competitive ERK inhibitors using HDX-MS and NMR and identify 14 new molecules with properties of R-state selection. They reveal effects propagated to distal regions in the P+1 and helix αF segments surrounding the activation loop, as well as helix αL16. Crystal structures of inhibitor complexes with ERK2 reveal systematic shifts in the Gly loop and helix αC, mediated by a Tyr-Tyr ring stacking interaction and the conserved Lys-Glu salt bridge. The findings suggest a model for the R-state involving small movements in the N-lobe that promote compactness within the kinase active site and alter mobility surrounding the activation loop. Such properties of conformation selection might be exploited to modulate the protein docking interface used by ERK substrates and effectors.